Document is current
Any future updates will be listed below
-
Authors
Raby, Martin
Servant, Euphrasie
Dangouloff-Ros, Volodia
Lebre, Anne-Sophie
Simboli, Giorgia Antonia
Saffroy, Raphaël
Benichi, Sandro
Bourgeois, Marie
Blauwblomme, Thomas
Onken, Julia
Koch, Arend
Schmid, Simone
Chrétien, Fabrice
Tauziède-Espariat, Arnault
Varlet, Pascale
Capper, David
Métais, Alice
-
Funding
Funding for this research was provided by:
Brain Tumour Charity (GN-000707)
- License Information
-
More Information
Article History
Received: 3 September 2025
Revised: 23 October 2025
Accepted: 11 November 2025
First Online: 18 November 2025
Declarations
:
: David Capper receives license fees from the sales of the IDH1 R132H mutation-specific antibody from DIANOVA GmbH/BIOZOL Diagnostics GmbH. David Capper further is a cofounder and a shareholder of Heidelberg Epignostix GmbH. The other authors declare that they have no conflicts of interest related to the topic of this article.
: Ethical approval for reporting the case from Charité Berlin was granted by the Charité Ethics Committee (EA2/053/25). Written informed consent or non-objection to participate in the study was provided by the patient’s legal guardian for patients from Hôpital Necker Enfants Malades.
